The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010.

TitleThe Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010.
Publication TypeJournal Article
Year of Publication2011
Authorsvan der Leest, RJT, de Vries, E, Bulliard, J-L, Paoli, J, Peris, K, Stratigos, AJ, Trakatelli, M, Maselis, TJEML, Situm, M, Pallouras, AC, Hercogova, J, Zafirovik, Z, Reusch, M, Olah, J, Bylaite, M, Dittmar, HC, Scerri, L, Correia, O, Medenica, L, Bartenjev, I, Guillen, C, Cozzio, A, Bogomolets, OV, del Marmol, V
JournalJ Eur Acad Dermatol Venereol
Volume25
Issue12
Pagination1455-65
Date Published2011 Dec
DOI10.1111/j.1468-3083.2011.04228.x
ISSN1468-3083
KeywordsBelgium, Female, Humans, Male, Melanoma, Questionnaires, Skin Neoplasms, Sunlight
Abstract

BACKGROUND: Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as 'Melanoma day'. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma.

OBJECTIVE: To evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas.

METHODS: Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine).

RESULTS: In total, 59,858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma; full body skin examination was performed in 72% of the screenees.

CONCLUSION: Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high-risk populations and by better use of dermoscopy and full body skin examination.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/21951235?dopt=Abstract

Alternate JournalJ Eur Acad Dermatol Venereol
Citation Key / SERVAL ID3119
PubMed ID21951235

                         

IUMSP | www.iumsp.ch
Institute of Social and Preventive Medicine
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top